Cancer immunology and immunotherapy
3 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austrian medical university strong in cancer immunology, brain simulation, and neurodegenerative disease research with three ERC Advanced Grants.
“Led three ERC Advanced Grants (EPIC, HOPE, POLICE) on cancer immunity mechanisms, and contributed to IMMUTRAIN, SECRET, and APERIM on cancer immunotherapy and tumor biology.”
PrimaryAT39 projects - LUXEMBOURG INSTITUTE OF HEALTH
Luxembourg biomedical research institute specializing in biomarker discovery, cancer immunoprofiling, and translational diagnostics across major disease areas.
“IMMUcan (largest project at EUR 2.7M, cancer immunoprofiling), REVERT (colorectal cancer therapy), EVIL (leukemia extracellular vesicles), and GLIOTRAIN (glioblastoma training network).”
PrimaryLU24 projects - INSTITUTO VALENCIANO DE ONCOLOGIA
Spanish oncology research institute specializing in cancer immunotherapy, pancreatic cancer, and biosensor-based early diagnosis.
“ULISES (2020-2024) focuses on immunological incompatibility and allogenic response as a mechanism for cancer treatment and vaccination, with IVO contributing oncological expertise.”
PrimaryES2 projects